Phase II
Despite not hitting endpoints, Cytokinetics noted that the FORTITUDE-ALS trial demonstrated consistency of effect for doses, endpoints and timepoints.
Less than one year after securing a toehold in the United States, Korea-based Enzychem Lifesciences hit a major milestone with its pipeline as it eyes completion of its Phase II CRIOM (Chemoradiation Induced Oral Mucositis) study, which could lead to eventual commercialization of a treatment for the serious cancer treatment by-product.
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
When major depressive disorder (MDD) does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it is reclassified as treatment-resistant depression or TRD. South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet its primary efficacy endpoints for TRD in a Phase II clinical trial.
Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
Up to 6 patients to be enrolled in the second cohort, initial data expected in fourth quarter 2019
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
The company indicated it was dropping LY2606368, prexasertib, a CHK1 drug in Phase II, and LY3023414, a PI3k/mTOR inhibitor that was also in Phase II.
MorphoSys AG, Galapagos NV and Novartis Pharma AG announced the initiation of GECKO, a phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
Galapagos NV, MorphoSys AG and Novartis Pharma AG announced the initiation of GECKO, a Phase 2 study testing a subcutaneous formulation of MOR106 in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.
PRESS RELEASES